Yuhei Morioka

1.5k total citations
8 papers, 149 citations indexed

About

Yuhei Morioka is a scholar working on Infectious Diseases, Molecular Biology and Hepatology. According to data from OpenAlex, Yuhei Morioka has authored 8 papers receiving a total of 149 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Infectious Diseases, 3 papers in Molecular Biology and 3 papers in Hepatology. Recurrent topics in Yuhei Morioka's work include Hepatitis C virus research (3 papers), SARS-CoV-2 and COVID-19 Research (2 papers) and HIV Research and Treatment (2 papers). Yuhei Morioka is often cited by papers focused on Hepatitis C virus research (3 papers), SARS-CoV-2 and COVID-19 Research (2 papers) and HIV Research and Treatment (2 papers). Yuhei Morioka collaborates with scholars based in Japan, South Korea and United States. Yuhei Morioka's co-authors include Takasuke Fukuhara, Yoshiharu Matsuura, Yuzy Fauzyah, Chikako Ono, Shiho Torii, Rigel Suzuki, Itsuki Anzai, Yusuke Maeda, Wataru Kamitani and Asuka Sato and has published in prestigious journals such as Journal of Virology, PLoS Pathogens and Cell Reports.

In The Last Decade

Yuhei Morioka

8 papers receiving 149 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yuhei Morioka Japan 5 93 41 27 22 19 8 149
Rakesh Sarkar India 9 117 1.3× 71 1.7× 30 1.1× 29 1.3× 7 0.4× 16 192
Beata Hukowska-Szematowicz Poland 7 105 1.1× 34 0.8× 48 1.8× 90 4.1× 14 0.7× 44 193
Daniel Mair United Kingdom 5 114 1.2× 35 0.9× 18 0.7× 8 0.4× 20 1.1× 8 146
Dylan Sheerin United Kingdom 8 74 0.8× 36 0.9× 40 1.5× 5 0.2× 8 0.4× 13 137
Christopher Monit United Kingdom 6 71 0.8× 31 0.8× 15 0.6× 15 0.7× 6 0.3× 7 113
Pamela C. De La Cruz-Rivera United States 5 90 1.0× 44 1.1× 24 0.9× 17 0.8× 23 1.2× 6 158
Marcos V. P. Gondim Brazil 6 82 0.9× 54 1.3× 49 1.8× 7 0.3× 18 0.9× 8 216
Donald M. Brandon United States 5 40 0.4× 19 0.5× 48 1.8× 11 0.5× 13 0.7× 8 102
Hataf Khan United Kingdom 6 67 0.7× 37 0.9× 20 0.7× 19 0.9× 6 0.3× 7 129

Countries citing papers authored by Yuhei Morioka

Since Specialization
Citations

This map shows the geographic impact of Yuhei Morioka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuhei Morioka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuhei Morioka more than expected).

Fields of papers citing papers by Yuhei Morioka

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuhei Morioka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuhei Morioka. The network helps show where Yuhei Morioka may publish in the future.

Co-authorship network of co-authors of Yuhei Morioka

This figure shows the co-authorship network connecting the top 25 collaborators of Yuhei Morioka. A scholar is included among the top collaborators of Yuhei Morioka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuhei Morioka. Yuhei Morioka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Tamura, Tomokazu, Hirotaka Yamamoto, Yuhei Morioka, et al.. (2024). A rapid and versatile reverse genetics approach for generating recombinant positive-strand RNA viruses that use IRES-mediated translation. Journal of Virology. 98(3). e0163823–e0163823. 1 indexed citations
2.
Tamura, Tomokazu, Hayato Ito, Shiho Torii, et al.. (2024). Akaluc bioluminescence offers superior sensitivity to track in vivo dynamics of SARS-CoV-2 infection. iScience. 27(5). 109647–109647. 4 indexed citations
3.
Tamura, Tomokazu, Shiho Torii, Kentaro Kajiwara, et al.. (2022). Secretory glycoprotein NS1 plays a crucial role in the particle formation of flaviviruses. PLoS Pathogens. 18(6). e1010593–e1010593. 7 indexed citations
4.
Suzuki, Rigel, Yuki Ono, Koji Noshita, et al.. (2022). Smoking enhances the expression of angiotensin‐converting enzyme 2 involved in the efficiency of severe acute respiratory syndrome coronavirus 2 infection. Microbiology and Immunology. 67(1). 22–31. 4 indexed citations
5.
Torii, Shiho, Chikako Ono, Rigel Suzuki, et al.. (2021). Establishment of a reverse genetics system for SARS-CoV-2 using circular polymerase extension reaction. Cell Reports. 35(3). 109014–109014. 97 indexed citations
6.
Fauzyah, Yuzy, Chikako Ono, Shiho Torii, et al.. (2020). Ponesimod suppresses hepatitis B virus infection by inhibiting endosome maturation. Antiviral Research. 186. 104999–104999. 15 indexed citations
7.
Ono, Chikako, Takasuke Fukuhara, Songling Li, et al.. (2020). Various miRNAs compensate the role of miR-122 on HCV replication. PLoS Pathogens. 16(6). e1008308–e1008308. 13 indexed citations
8.
Sato, Asuka, Chikako Ono, Tomokazu Tamura, et al.. (2020). Rimonabant suppresses RNA transcription of hepatitis B virus by inhibiting hepatocyte nuclear factor 4α. Microbiology and Immunology. 64(5). 345–355. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026